Cediranib - AstraZeneca

Drug Profile

Cediranib - AstraZeneca

Alternative Names: AZD-2171; Cediranib-maleate; Recentin; Zemfirza

Latest Information Update: 30 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Cancer Research UK; Institute of Cancer Research; Mario Negri Institute for Pharmacological Research; National Cancer Institute (Canada); National Cancer Institute (USA); Royal Marsden NHS Foundation Trust; University Health Network; University of Manchester; University of Oxford
  • Class Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ovarian cancer
  • Phase II Alveolar soft part sarcoma; Endometrial cancer; Prostate cancer; Solid tumours
  • Discontinued Acute myeloid leukaemia; Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioblastoma; Non-small cell lung cancer; Renal cell carcinoma; Soft tissue sarcoma

Most Recent Events

  • 18 Sep 2017 University College plans a phase III trial for Ovarian cancer(Combination therapy, Second-line therapy or greater, Maintenance Therapy) (NCT03278717)
  • 06 Jul 2017 AstraZeneca announces intention to submit NDA to US FDA for Ovarian cancer (Combination therapy, Second-line therapy or greater, Recurrent) in 2020 (AstraZeneca pipeline, July 2017)
  • 02 Jun 2017 Efficacy data from the phase III ICON6 trial in Ovarian Cancer presented at the 53rd annual meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top